Cox regression models on relapse-free and overall survival
| . | CN-AML . | All patients . |
|---|---|---|
| Relapse-free survival (HR, 95% CI) | ||
| Insertion site in the beta1-sheet | 2.05 (1.37-3.06) | 1.86 (1.29-2.67) |
| Overall survival | ||
| Insertion site in the beta1-sheet | 1.68 (1.17-2.42) | 1.59 (1.13-2.24) |
| Logarithm of WBC | 1.65 (1.17-2.31) | 1.50 (1.10-2.04) |
| CEBPAmut | 0.26 (0.10-0.72) | 0.31 (0.12-0.83) |
| Age (difference of 10 y) | 1.21 (1.00-1.46) | 1.22 (1.03-1.44) |
| . | CN-AML . | All patients . |
|---|---|---|
| Relapse-free survival (HR, 95% CI) | ||
| Insertion site in the beta1-sheet | 2.05 (1.37-3.06) | 1.86 (1.29-2.67) |
| Overall survival | ||
| Insertion site in the beta1-sheet | 1.68 (1.17-2.42) | 1.59 (1.13-2.24) |
| Logarithm of WBC | 1.65 (1.17-2.31) | 1.50 (1.10-2.04) |
| CEBPAmut | 0.26 (0.10-0.72) | 0.31 (0.12-0.83) |
| Age (difference of 10 y) | 1.21 (1.00-1.46) | 1.22 (1.03-1.44) |
CN-AML, cytogenetically normal AML; HR, hazard ratio; CI, confidence interval; WBC, white blood cell count; and CEBPAmut, mutation of the CCAAT/enhancer binding protein alpha.